Scinai Immunotherapeutics

The leading #UniversalFluVaccine candidate: Designed for multi-season multi-strain protection from seasonal & pandemic influenza; Phase 3 trial. (NASDAQ: $BVXV).

HQ location

Jerusalem, Israel

Website

Launch date

2003

Employees

Market cap

Enterprise value

$21m

Share price

$0.64 BVXV

Company register number

513436105

Recent deals

PinCell

https://twitter.com/biondvax http://www.facebook.com/pages/BiondVax-Pharmaceuticals-Ltd/180228491998332 https://www.linkedin.com/company/scinai/scinai.immunotherapeutics

Authorizing premium user...